For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and the formulated version represents a genuine change. These innovative therapies stabilize the transthyretin protein, halting its damaging build-up and alleviating the